89978-56-3

Usage

Uses

Used in Organic Synthesis:
1-Bromo-4-methoxy-2-methyl-5-nitrobenzene is used as a reagent in organic synthesis for building more complex molecules. Its presence of bromine, methoxy, and nitro groups allows for various chemical reactions, making it a versatile component in the synthesis of advanced organic compounds.
Used in Pharmaceutical Industry:
1-Bromo-4-methoxy-2-methyl-5-nitrobenzene is used as a building block in the pharmaceutical industry for the development of new drugs. Its unique structure can be modified and combined with other molecules to create potential therapeutic agents with specific pharmacological properties.
Safety Precautions:
It is important to handle 1-Bromo-4-methoxy-2-methyl-5-nitrobenzene with caution, as it may be harmful if inhaled, ingested, or in contact with the skin. Additionally, it may cause irritation to the respiratory system and eyes. Proper safety measures, such as wearing protective gear and working in a well-ventilated area, should be taken to minimize potential health risks.

Upstream product

• 27060-75-9 4-bromo-3-methylanisole 
• 100-84-5 1-methoxy-3-methyl-benzene 
• 182500-28-3 4-bromo-5-methyl-2-nitrophenol 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 808133-98-4 5-bromo-2-methoxy-4-methyl-aniline 
• 5456-94-0 2,4-dibromo-5-methylanisole 
• 1295504-00-5 1-[2-(4-methoxy-2-methyl-5-nitrophenylamino)phenyl]ethanone 
• 39538-68-6 2-methoxy-4-methylaniline 
• 1377582-21-2 4-Methoxy-2-methyl-5-nitro-benzamide 
• 182500-28-3 4-bromo-5-methyl-2-nitrophenol 

Relevant academic research and scientific papers

First Total Synthesis of a Cytotoxic Derivative of the Natural Product Aaptamine

A synthetic sequence to the benzonaphthyridinone framework is described. The key step is a one-pot, base-catalyzed vicarious nucleophilic substitution followed by ring closure. Additionally, the synthesis represents the application of a vicarious nucleoph

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological diso

Abnormal reactions of 2-methoxy-4,9-dimethyl-1-nitroacridine with selenous acid and selenium(IV) oxide. Synthesis of 1H-selenopheno[2,3,4-k,l]acridine-1- one: A new seleno-containing ring system

Unusual course of the reaction was revealed on the oxidation of functionally substituted acridine containing the activated methyl groups by well-known oxidants, such as selenous acid and selenium(IV) oxide. Treatment of 2-methoxy-4,9-dimethyl-1-nitroacridine (5) with an excess of H 2SeO3 in boiling ethanol gave a mixture of the normal reaction products, 2-methoxy-4-methyl-1-nitro-9-formylacridine (11) (isolated yield 29%) and 2-methoxy-4-methyl-1-nitroacridine-9-carboxylic acid (12) (36%), together with an abnormal product, 3-methoxy-5-methyl-1H-selenopheno[2,3,4-k,l] acridine-1-one (13) (21%), which is the first example of a new seleno-containing ring system. With the use of SeO2 the yield of selenolactone 13 was much lower.